Source Site (EDGAR)

Description of Completed Clinical Trials

Treatment of Myopia -1.0 to -3.0 diopters

For Efficacy Data Click Here
Excerpt From
KERAVISION INC /CA/
Form: 424B1   Filing Date: 8/13/99

<DOCUMENT> <TYPE>424B1 <SEQUENCE>1 <DESCRIPTION>FINAL PROSPECTUS DATED 08/12/1999 <TEXT> <PAGE> Clinical Trials Results Myopia. Since 1991, ophthalmic surgeons have utilized Intacs technology for the treatment of myopia in 1,787 patient eyes in clinical trials conducted in the United States and throughout the world. KeraVision's clinical trials have been designed to demonstrate the safety and efficacy of Intacs corneal ring segments and the safety of the surgical procedure used to insert Intacs. The safety and efficacy of Intacs corneal ring segments was evaluated using standard ophthalmic techniques. KeraVision initiated clinical trials using the initial design of Intacs in 1991 in both the United States and Brazil. In September 1994, KeraVision completed enrollment of a 90-patient FDA Phase II myopia trial using the initial design of Intacs. In September 1996, KeraVision completed enrollment of the group of 150 U.S. Phase II myopia patients with a modified design of Intacs. In November 1996, KeraVision initiated an expanded Phase II myopia trial involving 59 patient eyes to evaluate moderate myopia (- 3.5 to -5.0 diopters). In October 1996, KeraVision received FDA approval to commence a ten-center, 360-patient Phase III clinical trial for myopia in the United States and began that trial in December 1996. KeraVision completed the enrollment for the trial in May 1997. Our initial Pre-Market Approval (PMA) application was based on data from the PMA cohort, a group of 452 patients enrolled in the Intacs Phase II and Phase III clinical trials. Three thicknesses (0.25, 0.30 and 0.35mm) of Intacs corneal ring segments were evaluated. Intacs were successfully placed in 449 eyes out of 454 surgical attempts. After 12 months of follow-up, data were available for 97.6% of the PMA cohort patients. Intacs corneal ring segments have been removed from 39 patient eyes from the PMA cohort. Intacs corneal ring segments can be easily removed in a brief, outpatient procedure. The Intacs removal rate for the Phase III trial was 4.3% as compared to 9.6% from the earlier Phase II trial. Reasons for Intacs removals included: one for infection, 15 for patient dissatisfaction with correction achieved (undercorrection, overcorrection or induced astigmatism), 19 for patient dissatisfaction with visual symptoms (glare, halos, difficulty with night vision, etc.) and four for other reasons. There have been no clinically significant complications associated with Intacs removal procedures. The removal results demonstrate that the refractions returned to preoperative levels by three months following removal, in most instances. Best spectacle- corrected visual acuity was 20/20 or better in all cases following removal. The first procedure for the treatment of myopia using Intacs was performed in 1991, and to date more than 1,700 procedures have been conducted using Intacs corneal ring segment technology in clinical trials. Although KeraVision has developed eight-year clinical data on the safety and efficacy of Intacs in correcting myopia, it has limited long-term safety and efficacy data. We cannot assure you that long-term safety and efficacy data when collected will be consistent with these clinical trial results and will demonstrate that Intacs can be used safely and successfully to treat myopia in a broad segment of the population or on a long-term basis. All surgical procedures, including the Intacs placement procedure, involve some inherent risk of complications. For the PMA cohort, five patients experienced safety-related complications for an overall incident rate of 1.1%. All five patients recovered with no clinically significant effects. Adverse events include: one infection, one shallow Intacs corneal ring segment placement, one temporary loss of 2 lines of best corrected visual acuity and two corneal perforations. During the 12 months of follow up, there was a 4.5% incidence of removal and a 0.9% incidence of exchange procedures. Other complications included: overcorrection, reduction in central corneal sensation, difficulty with night vision, undercorrection, induced astigmatism, blurry vision, double vision, halos, glare, corneal blood vessels, and fluctuating distance vision. No patient has had a lasting injury to the eye or sustained any material loss of best corrected vision. In many patients, deposits have been observed in the stromal tunnel next to the Intacs corneal ring segments. In all cases, the deposits were confined to the stromal tunnel with no effect on patients' vision. Although KeraVision believes that these deposits are not complications, we cannot assure you that this will be the case on a long-term basis. All of these complications have also been observed in connection with other refractive surgery techniques. Although KeraVision believes these complications may be mitigated, KeraVision cannot assure you that these or other complications will not be serious or lasting or will not impair or preclude KeraVision from retaining existing regulatory approvals or obtaining regulatory approvals for our products or the acceptance of these products by patients or ophthalmologists. </text></plaintext></document> </body> </html>